Cancer Reversion Therapy: Prospects, Progress and Future Directions

Oisakede, Emmanuel O.; Olawade, David; Bello, Oluwakemi Jumoke; Analikwu, Claret Chinenyenwa; Egbon, Eghosasere; Fapohunda, Oluwaseun; Boussios, Stergios

Cancer Reversion Therapy: Prospects, Progress and Future Directions

Oisakede, Emmanuel O. ORCID: https://orcid.org/0009-0000-5791-301X, Olawade, David ORCID: https://orcid.org/0000-0003-0188-9836, Bello, Oluwakemi Jumoke, Analikwu, Claret Chinenyenwa, Egbon, Eghosasere, Fapohunda, Oluwaseun ORCID: https://orcid.org/0000-0001-6545-3471 and Boussios, Stergios ORCID: https://orcid.org/0000-0002-2512-6131 (2025) Cancer Reversion Therapy: Prospects, Progress and Future Directions. Current Issues in Molecular Biology, 47 (12). p. 1049.

Preview

Text
cimb-47-01049-v3.pdf - Published Version
Available under License Creative Commons Attribution.
| Preview

Official URL: https://doi.org/10.3390/cimb47121049

Abstract

Cancer reversion therapy represents a paradigm shift in oncology, focusing on reprogramming malignant cells to a non-malignant state rather than destroying them. This narrative review synthesizes current evidence, emerging technologies, and future directions in this promising field. Cancer reversion is founded on key biological observations: somatic cell reprogramming, spontaneous cancer regression, and microenvironmental influences on malignant behavior. Current approaches include epigenetic reprogramming using HDAC inhibitors and DNA methyltransferase inhibitors; microenvironmental modulation through extracellular matrix manipulation and vascular normalization; differentiation therapy exemplified by all-trans retinoic acid in acute promyelocytic leukemia; and targeting oncogene addiction as demonstrated in BCR-ABL-driven leukemias. Emerging technologies accelerating progress include single-cell analyses that reveal cancer heterogeneity and cellular state transitions; CRISPR-based approaches enabling precise genetic and epigenetic manipulation; patient-derived organoids that model tumor complexity; and artificial intelligence applications that identify novel reversion-inducing agents. Critical evaluation reveals that many reported “reversion” phenomena represent stimulus-dependent plasticity or transient growth arrest rather than stable phenotypic normalization. True cancer reversion requires durable, heritable phenotypic changes that persist after treatment withdrawal, with evidence of epigenetic consolidation and functional restoration. Despite promising advances, significant challenges remain: cancer cell plasticity facilitating therapeutic escape, difficulties in establishing stable reversion states, delivery challenges for solid tumors, and the need for combination approaches to address tumor heterogeneity. Future directions include integrated multi-omics analyses to comprehensively map cellular state transitions, studies of natural regression phenomena to identify reversion mechanisms, advanced nanodelivery systems for targeted therapy, and synthetic biology approaches creating intelligent therapeutic systems. By redirecting rather than destroying cancer cells, reversion therapy offers the potential for reduced toxicity and resistance, potentially transforming cancer from a deadly disease to a manageable condition.